LIVIVO - Search results -

Search results

Result 1 - 10 of total 16

Search options

Article: Whats new in 2020 ESC Guidelines for the management of acute coronary syndromes in patients presenting without persistent ST segment elevation?

Mrózek, Jan / Václavík, Jan

2022 Volume 68, Issue 5, Page(s) 324–331

Abstract: The article sumarizes the 2020 ESC Guidelines for the management of acute coronary syndromes (ACS) in patients presenting without persistent ST-segment elevation. The diagnostics of ACS consists in assessment of chest pain, EKG and cardiac troponin. ... ...

Title translation	Co je nového v Doporučených postupech ESC 2020 pro diagnostiku a léčbu akutních koronárních syndromů bez ST elevací?
Abstract	The article sumarizes the 2020 ESC Guidelines for the management of acute coronary syndromes (ACS) in patients presenting without persistent ST-segment elevation. The diagnostics of ACS consists in assessment of chest pain, EKG and cardiac troponin. Troponin should be evaluated by high sensitivity assay. 0h/1h algorithms should be used to rule-in or rule-out ACS. Patients with a positive troponin have higher risk of cardivascular events and mortality and the early invasive treatment should be applied in these patients. In the guidelines several antithrombotic stretegies for different clinical conditions are mentioned, where the cornerstone for the length and intensity of antithrombotic treatment is the evaluation of bleeding risk. Further on the revascularization aspects and strategies are debated in the guidelines. Finally there are mentioned two specific conditions of ACS - Myocardioal infarction with non-obstructive coronary arteries and Spontaneous coronary artery dissection.
MeSH term(s)	Humans ; Acute Coronary Syndrome/diagnosis ; Acute Coronary Syndrome/therapy ; Fibrinolytic Agents/therapeutic use ; Troponin ; Algorithms
Chemical Substances	Fibrinolytic Agents ; Troponin
Language	English
Publishing date	2022-09-30
Publishing country	Czech Republic
Document type	Journal Article
ZDB-ID	138213-5
ISSN	1801-7592 ; 0042-773X
ISSN (online)	1801-7592
ISSN	0042-773X
DOI	10.36290/vnl.2022.067
Database	MEDical Literature Analysis and Retrieval System OnLINE

In stock of ZB MED Cologne/Königswinter

Zs.B 327: Show issues			Location: Je nach Verfügbarkeit (siehe Angabe bei Bestand) bis Jg. 2021: Bestellungen von Artikeln über das Online-Bestellformular ab Jg. 2022: Lesesaal (EG)
Zs.MO 526: Show issues

Order via subito

This service is chargeable due to the Delivery terms set by subito. Orders including an article and supplementary material will be classified as separate orders. In these cases, fees will be demanded for each order.

Details ▾
- See ZB MED holdings
- Order with fees

Article ; Online: Impact of the COVID-19 pandemic on the occurrence and outcome of cardiogenic shock complicating acute myocardial infarction.

Motovska, Zuzana / Hlinomaz, Ota / Mrozek, Jan / Kala, Petr / Jarkovsky, Jiri

European journal of internal medicine

2023 Volume 115, Page(s) 134–136

MeSH term(s)	Humans ; Shock, Cardiogenic/therapy ; Shock, Cardiogenic/complications ; Pandemics ; COVID-19/complications ; COVID-19/epidemiology ; Myocardial Infarction/complications ; Myocardial Infarction/epidemiology ; Hospital Mortality ; Treatment Outcome
Language	English
Publishing date	2023-05-28
Publishing country	Netherlands
Document type	Letter
ZDB-ID	1038679-8
ISSN	1879-0828 ; 0953-6205
ISSN (online)	1879-0828
ISSN	0953-6205
DOI	10.1016/j.ejim.2023.05.032
Database	MEDical Literature Analysis and Retrieval System OnLINE

In stock of ZB MED Cologne/Königswinter

Zs.A 2608: Show issues

Location:
Je nach Verfügbarkeit (siehe Angabe bei Bestand)
bis Jg. 1994: Bestellungen von Artikeln über das Online-Bestellformular
Jg. 1995 - 2021: Lesesall (2.OG)
ab Jg. 2022: Lesesaal (EG)

Order via subito

Details ▾
- See ZB MED holdings
- Order with fees

Article: Prediction Score for persisting perfusion defects after pulmonary embolism.

Mrozek, Jan / Necasova, Tereza / Svoboda, Michal / Simkova, Iveta / Jansa, Pavel

Biomedical papers of the Medical Faculty of the University Palacky, Olomouc, Czechoslovakia

2019 Volume 164, Issue 4, Page(s) 394–400

Abstract: Aims: Long-term persistence of perfusion defect after pulmonaryembolism (PE) may lead to the development of chronic thromboembolic pulmonary hypertension. Identification of patients at risk of such a complication using a scoring system would be ... ...

Abstract	Aims: Long-term persistence of perfusion defect after pulmonaryembolism (PE) may lead to the development of chronic thromboembolic pulmonary hypertension. Identification of patients at risk of such a complication using a scoring system would be beneficial in clinical practice. Here, we aimed to derive a score for predicting persistence of perfusion defects after PE. Methods: 83 patients after PE were re-examined 6, 12 and 24 months after the PE episode. Data collected at the time of PE and perfusion status during follow-ups were used for modelling perfusion defects persistence using the Cox proportional hazards model and validated using bootstrap method. Results: A simple scoring system utilizing two variables (hemoglobin levels and age at the time of PE) was developed. Patients with hemoglobin levels over 140 g/L who were older than 65 years were at the highest risk of perfusion defects; in patients with the same hemoglobin levels and age <65 years, the risk was reduced by 79%, and by 89% in patients with hemoglobin <140 g/L. Conclusion: The proposed scoring system may be useful in clinical practice for identifying patients with high risk of persisting perfusion defects, flagging them for closer follow up, thus improving the effectiveness of long-term treatment of patients after PE.
MeSH term(s)	Adult ; Age Factors ; Aged ; Aged, 80 and over ; Anticoagulants/therapeutic use ; Clinical Decision Rules ; Echocardiography ; Female ; Hemoglobins/analysis ; Humans ; Hypertension, Pulmonary/drug therapy ; Hypertension, Pulmonary/etiology ; Male ; Middle Aged ; Proportional Hazards Models ; Pulmonary Embolism/complications ; Pulmonary Embolism/drug therapy ; Risk Factors
Chemical Substances	Anticoagulants ; Hemoglobins
Language	English
Publishing date	2019-09-13
Publishing country	Czech Republic
Document type	Comparative Study ; Journal Article
ZDB-ID	17196-7
ISSN	1804-7521 ; 1213-8118 ; 0231-5599 ; 0862-481X
ISSN (online)	1804-7521
ISSN	1213-8118 ; 0231-5599 ; 0862-481X
DOI	10.5507/bp.2019.033
Database	MEDical Literature Analysis and Retrieval System OnLINE

In stock of ZB MED Cologne/Königswinter

Zs.A 6675: Show issues

Location:
Je nach Verfügbarkeit (siehe Angabe bei Bestand)
bis Jg. 2021: Bestellungen von Artikeln über das Online-Bestellformular
ab Jg. 2022: Lesesaal (EG)

Order via subito

Details ▾
- See ZB MED holdings
- Order with fees

Article ; Online: The Prognosis of Cardiogenic Shock Following Acute Myocardial Infarction-an Analysis of 2693 Cases From a Prospective Multicenter Registry.

Muzafarova, Tamilla / Motovska, Zuzana / Hlinomaz, Ota / Kala, Petr / Hromadka, Milan / Precek, Jan / Mrozek, Jan / Matejka, Jan / Kettner, Jiri / Bis, Josef / Jarkovsky, Jiri

Deutsches Arzteblatt international

2023 Volume 120, Issue 31-32, Page(s) 538–539

MeSH term(s)	Humans ; Shock, Cardiogenic/diagnosis ; Shock, Cardiogenic/etiology ; Shock, Cardiogenic/therapy ; Prospective Studies ; Myocardial Infarction/complications ; Myocardial Infarction/diagnosis ; Prognosis
Language	English
Publishing date	2023-09-18
Publishing country	Germany
Document type	Multicenter Study ; Letter
ZDB-ID	2406159-1
ISSN	1866-0452 ; 1866-0452
ISSN (online)	1866-0452
ISSN	1866-0452
DOI	10.3238/arztebl.m2023.0102
Database	MEDical Literature Analysis and Retrieval System OnLINE

Order via subito

Article ; Online: Utilization of healthcare services in acute myocardial infarction and the risk of out-of-hospital cardiac death.

Motovska, Zuzana / Hlinomaz, Ota / Hromadka, Milan / Mrozek, Jan / Precek, Jan / Kala, Petr / Muzafarova, Tamilla / Kettner, Jiri / Matejka, Jan / Bis, Josef / Cervinka, Pavel / Tomasov, Pavol / Klechova, Anna / Sanca, Ondrej / Jarkovsky, Jiri

Panminerva medica

2023 Volume 66, Issue 1, Page(s) 79–81

MeSH term(s)	Humans ; Myocardial Infarction/epidemiology ; Myocardial Infarction/therapy ; Hospitals ; Delivery of Health Care
Language	English
Publishing date	2023-08-03
Publishing country	Italy
Document type	Journal Article
ZDB-ID	123572-2
ISSN	1827-1898 ; 0031-0808
ISSN (online)	1827-1898
ISSN	0031-0808
DOI	10.23736/S0031-0808.23.04910-8
Database	MEDical Literature Analysis and Retrieval System OnLINE

In stock of ZB MED Cologne/Königswinter

Zs.B 179: Show issues

Location:
Je nach Verfügbarkeit (siehe Angabe bei Bestand)
bis Jg. 2021: Bestellungen von Artikeln über das Online-Bestellformular
ab Jg. 2022: Lesesaal (EG)

Order via subito

Details ▾
- See ZB MED holdings
- Order with fees

Article ; Online: Outcomes of patients with myocardial infarction and cardiogenic shock treated with culprit vessel-only versus multivessel primary PCI.

Hlinomaz, Ota / Motovska, Zuzana / Kala, Petr / Hromadka, Milan / Precek, Jan / Mrozek, Jan / Červinka, Pavel / Kettner, Jiri / Matejka, Jan / Zohoor, Ahmad / Bis, Josef / Jarkovsky, Jiri

Hellenic journal of cardiology : HJC = Hellenike kardiologike epitheorese

2023 Volume 76, Page(s) 1–10

Abstract: Introduction and objectives: Multivessel primary percutaneous coronary intervention (pPCI) is still often used in patients with ST-elevation myocardial infarction (STEMI) and cardiogenic shock (CS). The study aimed to compare the characteristics and ... ...

Abstract	Introduction and objectives: Multivessel primary percutaneous coronary intervention (pPCI) is still often used in patients with ST-elevation myocardial infarction (STEMI) and cardiogenic shock (CS). The study aimed to compare the characteristics and prognosis of patients with CS-STEMI and multivessel coronary disease (MVD) treated with culprit vessel-only pPCI or multivessel-pPCI during the initial procedure. Material and methods: From 2016 to 2020, 23,703 primary PCI patients with STEMI were included in a national all-comers registry of cardiovascular interventions. Of them, 1,213 (5.1%) patients had CS and MVD at admission to the hospital. Initially, 921 (75.9%) patients were treated with culprit vessel (CV)-pPCI and 292 (24.1%) with multivessel (MV)-pPCI. Results: Patients with 3-vessel disease and left main disease had a higher probability of being treated with MV-pPCI than patients with 2-vessel disease and patients without left main disease (28.5% vs. 18.6%; p < 0.001 and 37.7% vs. 20.6%; p < 0.001). Intra-aortic balloon pump, extracorporeal membrane oxygenation (ECMO), and other mechanical circulatory support systems were more often used in patients with MV-pPCI. Thirty (30)-day and 1-year all-cause mortality rates were similar in the CV-pPCI and MV-pPCI groups (odds ratio, 1.01; 95% confidence interval [CI] 0.77 to 1.32; p = 0.937 and 1.1; 95% CI 0.84 to 1.44; p = 0.477). The presence of 3-vessel disease and the use of ECMO were the strongest adjusted predictors of 30-day and 1-year mortality. Conclusions: Our data from an extensive all-comers registry suggests that selective use of MV-pPCI does not increase the all-cause mortality rate in patients with CS-STEMI and MVD compared to CV-pPCI.
MeSH term(s)	Humans ; Shock, Cardiogenic/etiology ; Shock, Cardiogenic/therapy ; Coronary Artery Disease/complications ; Coronary Artery Disease/surgery ; Percutaneous Coronary Intervention/methods ; ST Elevation Myocardial Infarction/complications ; ST Elevation Myocardial Infarction/surgery ; Treatment Outcome ; Risk Factors ; Myocardial Infarction/complications ; Myocardial Infarction/therapy
Language	English
Publishing date	2023-08-24
Publishing country	Netherlands
Document type	Journal Article
ZDB-ID	2215027-4
ISSN	2241-5955 ; 1109-9666
ISSN (online)	2241-5955
ISSN	1109-9666
DOI	10.1016/j.hjc.2023.08.009
Database	MEDical Literature Analysis and Retrieval System OnLINE

In stock of ZB MED Cologne/Königswinter

Zs.A 6187: Show issues

Location:
Je nach Verfügbarkeit (siehe Angabe bei Bestand)
bis Jg. 2021: Bestellungen von Artikeln über das Online-Bestellformular
ab Jg. 2022: Lesesaal (EG)

Order via subito

Details ▾
- See ZB MED holdings
- Order with fees

Article: Reperfusion after pulmonary embolism - long-term follow-up, risk factors, clinical impact.

Mrozek, Jan / Petrova, Jana / Vaclavkova, Jana / Janovsky, Vladimir / Kraus, Lubos / Jansa, Pavel

Biomedical papers of the Medical Faculty of the University Palacky, Olomouc, Czechoslovakia

2018 Volume 162, Issue 2, Page(s) 121–126

Abstract: Background and aim: Thromboembolic disease is the third most common cardiovascular disorder and deep vein thrombosis carries the risk of pulmonary embolism (PE). Questions related to reperfusion after PE remain, especially risk factors. Incomplete ... ...

Abstract	Background and aim: Thromboembolic disease is the third most common cardiovascular disorder and deep vein thrombosis carries the risk of pulmonary embolism (PE). Questions related to reperfusion after PE remain, especially risk factors. Incomplete reperfusion after PE is closely related to the development of chronic thromboembolic pulmonary hypertension. The aim of this study was to determine the relation between reperfusion after PE in the long term over a period of 24 months, laboratory results and clinical risk factors found during the initial PE event. Patients and methods: 85 consecutive patients with a first episode of acute PE, diagnosed at 4 cardiology clinics, were followed up using clinical evaluation, scintigraphy and echocardiography (6, 12 and 24 months after the PE. 35 patients were in the low risk category (41%), 42 (49%) in the intermediate risk group and 8 (9%) in the high risk category. Results: Perfusion defects persisted in 20 patients (26%) after 6 months, in 19 patients (25%) after 12 months and in 14 patients (19%) after 24 months. The incidence was more frequent in older patients, with more serious (higher risk) PE, increased right ventricular internal diameter during the initial episode, and more significant tricuspid insufficiency in the initial echocardiography. Notably, higher hemoglobin levels were also shown as a significant risk factor. The presence of perfusion defects after 24 months correlated with a concurrent higher pulmonary pressure but not with either patient function or adverse events (recurrence of PE, re-hospitalization or bleeding). In 3 cases (4% of patients), long-term echocardiographic evidence of pulmonary hypertension was detected. Conclusion: Even after 24 months from acute PE with adequate anticoagulation treatment, incomplete reperfusion was found in 19% of patients with a corresponding risk of chronic thromboembolic pulmonary disease and hypertension.
MeSH term(s)	Adult ; Aged ; Anticoagulants/therapeutic use ; Computed Tomography Angiography ; Echocardiography ; Female ; Follow-Up Studies ; Humans ; Male ; Middle Aged ; Multimodal Imaging ; Perfusion Imaging ; Prospective Studies ; Pulmonary Embolism/diagnostic imaging ; Pulmonary Embolism/drug therapy ; Reperfusion/methods ; Risk Factors ; Thrombolytic Therapy/methods ; Young Adult
Chemical Substances	Anticoagulants
Language	English
Publishing date	2018-01-24
Publishing country	Czech Republic
Document type	Journal Article ; Multicenter Study
ZDB-ID	17196-7
ISSN	1804-7521 ; 1213-8118 ; 0231-5599 ; 0862-481X
ISSN (online)	1804-7521
ISSN	1213-8118 ; 0231-5599 ; 0862-481X
DOI	10.5507/bp.2018.001
Database	MEDical Literature Analysis and Retrieval System OnLINE

In stock of ZB MED Cologne/Königswinter

Zs.A 6675: Show issues

Location:
Je nach Verfügbarkeit (siehe Angabe bei Bestand)
bis Jg. 2021: Bestellungen von Artikeln über das Online-Bestellformular
ab Jg. 2022: Lesesaal (EG)

Order via subito

Details ▾
- See ZB MED holdings
- Order with fees

Article ; Online: The relationship between symptom onset-to-needle time and ischemic outcomes in patients with acute myocardial infarction treated with primary PCI: Observations from Prague-18 Study.

Hromadka, Milan / Motovska, Zuzana / Hlinomaz, Ota / Kala, Petr / Varvarovsky, Ivo / Dusek, Jaroslav / Svoboda, Michal / Jarkovsky, Jiri / Tousek, Frantisek / Jansky, Pavel / Simek, Stanislav / Branny, Marian / Mrozek, Jan / Miklik, Roman / Rokyta, Richard / Widimsky, Petr

Journal of cardiology

2021 Volume 79, Issue 5, Page(s) 626–633

Abstract: Objectives: Based on previous studies with clopidogrel, the time between acute myocardial infarction (AMI) symptoms onset and primary percutaneous coronary intervention (PCI) was proven as important prognostic factor. Our aim was to assess the ... ...

Abstract	Objectives: Based on previous studies with clopidogrel, the time between acute myocardial infarction (AMI) symptoms onset and primary percutaneous coronary intervention (PCI) was proven as important prognostic factor. Our aim was to assess the relationship between symptoms onset to needle time (SNT) and procedural results and the occurrence of ischemic endpoints in primary angioplasty patients treated with potent P2Y12 inhibitors. Methods: A total of 1,131 out of 1,230 patients randomized to the Prague-18 study (prasugrel vs. ticagrelor in primary PCI) were divided into a high and a low-risk group. The effect of defined SNT on patients' ischemic endpoints and prognosis by their risk status at admission was tested. Results: The median SNT was 3.2 hours. Longer SNTs resulted in a more frequent incidence of TIMI flow <3 post PCI (p=0.015). There were significant differences in the occurrence of the combined ischemic endpoint among the compared SNT groups at 30 days (p=0.032), and 1 year (p=0.011), with the highest incidence in the ≤1 h SNT group of patients. "Latecomers" (SNT>4 hs) in the high-risk group experienced more reinfarction within 1 year [OR (95% CI) 3.23 (1.09-9.62) p=0.035]; no difference was found in the low-risk group. Conclusions: In the era of intense antithrombotic medication, stratification of MI patients undergoing primary angioplasty, based on initial ischemic risk assessment affected prognosis more than symptom onset to needle time. Longer time delay was significantly related to increased incidence of ischemic events and all-cause mortality only in patients with high ischemic risk.
MeSH term(s)	Clopidogrel ; Humans ; Myocardial Infarction ; Percutaneous Coronary Intervention/adverse effects ; Platelet Aggregation Inhibitors/therapeutic use ; Prasugrel Hydrochloride ; Treatment Outcome
Chemical Substances	Platelet Aggregation Inhibitors ; Clopidogrel (A74586SNO7) ; Prasugrel Hydrochloride (G89JQ59I13)
Language	English
Publishing date	2021-12-16
Publishing country	Netherlands
Document type	Journal Article ; Randomized Controlled Trial ; Research Support, Non-U.S. Gov't
ZDB-ID	639364-0
ISSN	1876-4738 ; 0386-2887 ; 0914-5087
ISSN (online)	1876-4738
ISSN	0386-2887 ; 0914-5087
DOI	10.1016/j.jjcc.2021.11.015
Database	MEDical Literature Analysis and Retrieval System OnLINE

In stock of ZB MED Cologne/Königswinter

Zs.A 1794: Show issues

Location:
Je nach Verfügbarkeit (siehe Angabe bei Bestand)
bis Jg. 1994: Bestellungen von Artikeln über das Online-Bestellformular
Jg. 1995 - 2021: Lesesall (1.OG)
ab Jg. 2022: Lesesaal (EG)

Order via subito

Details ▾
- See ZB MED holdings
- Order with fees

Article: Safety of early discharge in low risk patients after acute ST-segment elevation myocardial infarction, treated with primary percutaneous coronary intervention. Open label, randomized trial.

Novobilsky, Kamil / Stipal, Roman / Cerny, Petr / Horak, Ivo / Kaucak, Vladimir / Mrozek, Jan / Vaclavik, Jan / Kryza, Radim

Biomedical papers of the Medical Faculty of the University Palacky, Olomouc, Czechoslovakia

2018 Volume 163, Issue 1, Page(s) 61–66

Abstract: Background: The length of hospital stay in patients with acute myocardial infarction and ST-segment elevation (STEMI) has been shortened in recent years with corresponding savings in costs, but there is limited available data on its implementation in ... ...

Abstract	Background: The length of hospital stay in patients with acute myocardial infarction and ST-segment elevation (STEMI) has been shortened in recent years with corresponding savings in costs, but there is limited available data on its implementation in clinical practice. The aim of this trial was to determine whether early discharge in selected patients after STEMI is feasible and safe. Methods: 151 patients with STEMI successfully treated with primary percutaneous coronary intervention (PCI) who fulfilled the inclusion criteria of low risk were randomly assigned to two groups on a 1:1 ratio: early (within 48-72 h of admission) and standard (after 72 h) discharge. The primary end point was the composite of death, myocardial infarction (MI), unstable angina, stroke, unplanned rehospitalization, repeated target vessel revascularization and stent thrombosis at 90 days after discharge. The study is registered with ClinicalTrials.gov (identifier NCT02023983). Results: The primary end point occurred in 5 patients in the early group and 6 in the standard group (6.6% vs. 8.0%, P=0.765). There were no significant differences in the incidence of individual components of the primary end point at 90 days. The length of hospital stay was significantly shorter in the intervention group (60.8 ± 8.5 vs. 92.1 ± 12.1 h, P<0.0001). Conclusion: This study confirms that early discharge within 48-72 h in selected low risk patients after STEMI treated with successful primary PCI is feasible and safe, with outcomes comparable to the later discharge. This strategy applies to more than a quarter of all STEMI patients.
MeSH term(s)	Aged ; Continuity of Patient Care/standards ; Female ; Humans ; Length of Stay/statistics & numerical data ; Male ; Monitoring, Physiologic ; Patient Discharge/standards ; Percutaneous Coronary Intervention ; Prospective Studies ; ST Elevation Myocardial Infarction/physiopathology ; ST Elevation Myocardial Infarction/surgery ; Time Factors ; Treatment Outcome
Language	English
Publishing date	2018-08-28
Publishing country	Czech Republic
Document type	Journal Article ; Randomized Controlled Trial
ZDB-ID	17196-7
ISSN	1804-7521 ; 1213-8118 ; 0231-5599 ; 0862-481X
ISSN (online)	1804-7521
ISSN	1213-8118 ; 0231-5599 ; 0862-481X
DOI	10.5507/bp.2018.041
Database	MEDical Literature Analysis and Retrieval System OnLINE

In stock of ZB MED Cologne/Königswinter

Zs.A 6675: Show issues

Location:
Je nach Verfügbarkeit (siehe Angabe bei Bestand)
bis Jg. 2021: Bestellungen von Artikeln über das Online-Bestellformular
ab Jg. 2022: Lesesaal (EG)

Order via subito

Details ▾
- See ZB MED holdings
- Order with fees

Article ; Online: The prognostic significance of periprocedural infarction in the era of potent antithrombotic therapy. The PRAGUE-18 substudy.

Dusek, Jaroslav / Motovska, Zuzana / Hlinomaz, Ota / Miklik, Roman / Hromadka, Milan / Varvarovsky, Ivo / Jarkovsky, Jiri / Tousek, Frantisek / Majtan, Bohumil / Simek, Stanislav / Branny, Marian / Mrozek, Jan / Widimsky, Petr

International journal of cardiology

2020 Volume 319, Page(s) 1–6

Abstract: Background: The prognostic significance of periprocedural myocardial infarction (MI) remains controversial.: Methods and results: The study aims to investigate the incidence of periprocedural MI in the era of high sensitivity diagnostic markers and ... ...

Abstract	Background: The prognostic significance of periprocedural myocardial infarction (MI) remains controversial. Methods and results: The study aims to investigate the incidence of periprocedural MI in the era of high sensitivity diagnostic markers and intense antithrombotics, and its impact on early outcomes of patients with acute MI treated with primary angioplasty (pPCI). Data from the PRAGUE-18 (prasugrel versus ticagrelor in pPCI) study were analyzed. The primary net-clinical endpoint (EP) included death, spontaneous MI, stroke, severe bleeding, and revascularization at day 7. The key secondary efficacy EP included cardiovascular death, spontaneous MI, and stroke within 30 days. The incidence of peri-pPCI MI was 2.3% (N = 28) in 1230 study patients. The net-clinical EP occurred in 10.7% of patients with, and in 3.6% of patients without, peri-pPCI MI (HR 2.92; 95% CI 0.91-9.38; P = 0.059). The key efficacy EP was 10.7% and 3.2%, respectively (HR 3.44; 95% CI 1.06-11.13; P = 0.028). Patients with periprocedural MI were at a higher risk of spontaneous MI (HR 6.19; 95% CI 1.41-27.24; P = 0.006) and stent thrombosis (HR 10.77; 95% CI 2.29-50.70; P = 0.003) within 30 days. Age, hyperlipidemia, multi-vessel disease, post-procedural TIMI <3, pPCI on circumflex coronary artery, and periprocedural GP IIb/IIIa inhibitor were independent predictors of peri-pPCI MI. Conclusions: In the era of intense antithrombotic therapy, the occurrence of peri-pPCI MI is despite highly sensitive diagnostic markers a rare complication, and is associated with an increased risk of early reinfarction and stent thrombosis.
MeSH term(s)	Fibrinolytic Agents/adverse effects ; Fibrinolytic Agents/therapeutic use ; Humans ; Percutaneous Coronary Intervention ; Platelet Aggregation Inhibitors ; Prasugrel Hydrochloride ; Prognosis ; Risk Factors ; Treatment Outcome
Chemical Substances	Fibrinolytic Agents ; Platelet Aggregation Inhibitors ; Prasugrel Hydrochloride (G89JQ59I13)
Language	English
Publishing date	2020-07-04
Publishing country	Netherlands
Document type	Journal Article
ZDB-ID	779519-1
ISSN	1874-1754 ; 0167-5273
ISSN (online)	1874-1754
ISSN	0167-5273
DOI	10.1016/j.ijcard.2020.06.067
Database	MEDical Literature Analysis and Retrieval System OnLINE

In stock of ZB MED Cologne/Königswinter

Zs.A 1673: Show issues

Location:
Je nach Verfügbarkeit (siehe Angabe bei Bestand)
bis Jg. 1994: Bestellungen von Artikeln über das Online-Bestellformular
Jg. 1995 - 2021: Lesesall (1.OG)
ab Jg. 2022: Lesesaal (EG)

Order via subito

Details ▾
- See ZB MED holdings
- Order with fees

To top

More links

Kategorien

In stock of ZB MED Cologne/Königswinter

Order via subito

More links

Kategorien

In stock of ZB MED Cologne/Königswinter

Order via subito

More links

Kategorien

In stock of ZB MED Cologne/Königswinter

Order via subito

More links

Kategorien

Order via subito

More links

Kategorien

In stock of ZB MED Cologne/Königswinter

Order via subito

More links

Kategorien

In stock of ZB MED Cologne/Königswinter

Order via subito

More links

Kategorien

In stock of ZB MED Cologne/Königswinter

Order via subito

More links

Kategorien

In stock of ZB MED Cologne/Königswinter

Order via subito

More links

Kategorien

In stock of ZB MED Cologne/Königswinter

Order via subito

More links

Kategorien

In stock of ZB MED Cologne/Königswinter

Order via subito